Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
Last trade$51.89
Day change-$3.07 (-5.59%)
Day range$51.34 – $57.85
Volume41,414
Market cap$180M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SLGL.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SLGL, quarterly periods
Line item
Q2 FY2020 Jun 30, 2020
Q2 FY2019 Jun 30, 2019
Revenue
$1.13M
$7.79M
Cost of revenue
$0
$0
Gross profit
$1.13M
$7.79M
Selling, general and administrative
$2.23M
$1.64M
Research and development
$6.45M
$11.44M
Total operating expenses
$8.68M
$13.08M
Operating income
-$7.55M
-$5.29M
Interest expense
—
—
Income before taxes
-$7.07M
-$4.93M
Income taxes
—
—
Net income
-$7.07M
-$4.93M
Net income attributable to common shareholders
-$7.07M
-$4.93M
EBITDA
-$7.55M
-$5.29M
Basic earnings per share
-$3.10
-$2.60
Diluted earnings per share
-$3.10
-$2.60
Recent news
Company coverage with links to the original publishers.
Supernus Pharmaceuticals beat Q3 2026 earnings expectations with $0.93 EPS versus consensus of $0.49, representing an 89.80% surprise. Revenue of $226.77 million also exceeded estimates by 1.39%. However, the stock has underperformed the market by 17.3% year-to-date and carries a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revision trends ahead of the earnings release.
Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.
Sol-Gel Technologies Ltd. (SLGL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 41.9% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, generating approximately $33.1 million in gross proceeds. The offering, expected to close on March 25, 2026, includes participation from multiple institutional investors. Net proceeds will fund continued development of SGT-610, a Phase 3 topical hedgehog inhibitor for basal cell carcinoma prevention in Gorlin syndrome patients, along with working capital and general corporate purposes.
Over 22 pharmaceutical companies are developing new drugs for basal cell neoplasms, with promising therapies targeting various molecular pathways and showing potential in clinical trials.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.